Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Edgewise Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapies for severe muscle diseases, including muscular dystrophies and cardiac disorders. Its core programs target muscle damage and dysfunction through proprietary precision medicine platforms, with lead candidates like sevasemten and EDG-7500 designed to protect muscle fibers and improve function. The company aims to address unmet needs in rare neuromuscular and cardiovascular conditions worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.